<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-92041" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Thrombolysis In Myocardial Infarction Risk Score</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rao</surname>
            <given-names>Suman S.</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Agasthi</surname>
            <given-names>Pradyumna</given-names>
          </name>
          <aff>Mayo Clinic Rochester</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Suman Rao declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pradyumna Agasthi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-92041.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">Patients who initially present with signs and symptoms of unstable angina or non-ST elevated myocardial infarction require risk stratification. The need for this stratification is two-fold. Primarily, it helps in making decisions about patient management. Additionally, it helps predict the likelihood of adverse cardiac events.</p>
        <p>The thrombolysis in myocardial infarction (TIMI) score is considered a tool for early risk stratification. According to several trials, notably TIMI 11B and ESSENCE, seven factors help assess the mortality risk and risk of other adverse cardiac events, as listed below.<xref ref-type="bibr" rid="article-92041.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Age of 65 years or older</p>
          </list-item>
          <list-item>
            <p>Presence of at least three risk factors for coronary artery disease (i.e., diabetes mellitus, hypertension, hyperlipidemia, smoking, family history)</p>
          </list-item>
          <list-item>
            <p>Previous history of coronary stenosis of 50% or more</p>
          </list-item>
          <list-item>
            <p>Presence of greater than or equal to&#x000a0;2 episodes of angina 24 hours before the presentation</p>
          </list-item>
          <list-item>
            <p>Aspirin use in the past seven days</p>
          </list-item>
          <list-item>
            <p>ST-segment deviations greater than or equal to 0.05 mV on initial ECG at admission</p>
          </list-item>
          <list-item>
            <p>Elevated serum cardiac markers of necrosis</p>
          </list-item>
        </list>
        <p>If present, each factor contributes a value of one point toward the TIMI risk score, making it a simple tool that does not require differential weights for each factor. A higher score implies a higher likelihood of adverse cardiac events and/or risk of mortality. The following represents scores paired with the percent risk of mortality, new/recurrent MI, or severe ischemia requiring further invasive cardiac intervention.</p>
        <list list-type="bullet">
          <list-item>
            <p>4.7% for a score of 0/1</p>
          </list-item>
          <list-item>
            <p>8.3% for a score of 2</p>
          </list-item>
          <list-item>
            <p>13.2% for a score of 3</p>
          </list-item>
          <list-item>
            <p>19.9% for a score of 4</p>
          </list-item>
          <list-item>
            <p>26.2% for a score of 5</p>
          </list-item>
          <list-item>
            <p>40.9% for a score of 6/7</p>
          </list-item>
        </list>
        <p>Scores ranging from 0-2 constitute a low risk. Scores from 3-5 are considered intermediate risk. A score of 6 or 7 indicates high risk.<xref ref-type="bibr" rid="article-92041.r2">[2]</xref></p>
        <p>Studies have shown that the TIMI risk score is far superior in providing diagnostic evidence for acute coronary syndrome (ACS) compared to history, physical examination, EKG&#x02019;s, or biomolecular cardiac markers alone.<xref ref-type="bibr" rid="article-92041.r3">[3]</xref><xref ref-type="bibr" rid="article-92041.r4">[4]</xref></p>
      </sec>
      <sec id="article-92041.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Apart from the TIMI risk score, there are other predictive tools such as the GRACE, PAMI, and CADILLAC risk scores that provide insight into management and mortality risk assessment. Studies have shown that the CADILLAC score was more helpful in predicting six-month to one-year outcomes.<xref ref-type="bibr" rid="article-92041.r5">[5]</xref>&#x000a0;However, other studies have shown that the TIMI, CADILLAC, and PAMI scores were superior to the GRACE score in determining high-risk patients in need of cardiac catheterization.<xref ref-type="bibr" rid="article-92041.r6">[6]</xref></p>
      </sec>
      <sec id="article-92041.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The TIMI risk score was found to be predictive of the severity of the vascular disease, making it a powerful tool to predict the potential blood vessels of coronary circulation that could be involved.</p>
        <p>A sub-study of PRISM-PLUS compared TIMI risk scores to findings on coronary angiography. The study found that patients who had a risk score of 5&#x000a0;to 7 were significantly more likely to have severe culprit stenosis, multivessel disease, left main coronary artery disease, or visible thrombus compared to those who were in the low-risk score category.<xref ref-type="bibr" rid="article-92041.r7">[7]</xref></p>
        <p>Studies have also noted that of the seven factors that contribute to the TIMI risk score, history of coronary artery disease, age greater than or equal to 65, and deviations in ST-segment on initial EKG&#x02019;s were more strongly associated with adverse cardiac events as compared to the other factors.<xref ref-type="bibr" rid="article-92041.r8">[8]</xref></p>
        <p>Recent studies have also shown that the amplitude of ST-segment elevation or depression and the degree of cardiac biomarker elevation (troponin T/I) can both be independent factors that could point toward initiating early invasive cardiac procedures.<xref ref-type="bibr" rid="article-92041.r9">[9]</xref></p>
      </sec>
      <sec id="article-92041.s4" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>Perhaps the greatest utility that the TIMI score has to offer is its ability to guide the management of patients presenting with signs of unstable angina/non-ST elevated myocardial infarctions (UA/NSTEMI).</p>
        <p>The TACTICS-TIMI 18 trial compared outcomes of patients presenting with UA/NSTEMI who underwent either early invasive interventions or conservative treatment with medication. After risk stratifying patients, they found that intermediate or high-risk patients who underwent invasive cardiac intervention showed a significant decrease in death, nonfatal MI, and rehospitalization for cardiac events compared to those who were medically managed. There was no significant difference in outcome between low-risk patients who received early intervention and those who received medical management.<xref ref-type="bibr" rid="article-92041.r10">[10]</xref></p>
        <p>The timing at which certain complications enfold has been another factor of interest. The TIMI 11b and ESSENCE trials have shown that nearly one-third of myocardial infarctions and half the number of deaths occur after the first week of presentation. Further studies have taken data from these trials and have shown that nearly a quarter of adverse cardiac events occur within 6 weeks following&#x000a0;discharge.<xref ref-type="bibr" rid="article-92041.r8">[8]</xref>&#x000a0;Patients who were stratified as high risk had a greater likelihood of presenting with adverse cardiac events. However, high-risk patients treated with enoxaparin had a significantly reduced risk of major cardiac events on discharge compared to patients treated with unfractionated heparin.<xref ref-type="bibr" rid="article-92041.r1">[1]</xref></p>
        <p>The PRISM-PLUS study sought to highlight the importance of glycoprotein IIb/IIIa inhibitors. The study showed a significant benefit of the use of glycoprotein IIb/IIIa inhibitors with aspirin and heparin in patients with a TIMI score of greater than 4 compared to management with aspirin and heparin alone. Glycoprotein IIb/IIIa inhibitors were shown to decrease the level of myocardial injury, as measured by peak troponin and creatinine kinase levels.<xref ref-type="bibr" rid="article-92041.r7">[7]</xref></p>
        <p>In conclusion, early invasive management, such as cardiac angiography and revascularization, is recommended for patients presenting with a TIMI risk score greater than or equal to 3. Patients with a TIMI risk score of 0&#x000a0;to 2 should be managed medically.</p>
      </sec>
      <sec id="article-92041.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=92041&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=92041">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/92041/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=92041">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-92041.s6">
        <title>References</title>
        <ref id="article-92041.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bernink</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Horacek</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Papuchis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mautner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Corbalan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Radley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.</article-title>
            <source>JAMA</source>
            <year>2000</year>
            <month>Aug</month>
            <day>16</day>
            <volume>284</volume>
            <issue>7</issue>
            <fpage>835</fpage>
            <page-range>835-42</page-range>
            <pub-id pub-id-type="pmid">10938172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-92041.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Snapinn</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Theroux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.</article-title>
            <source>Eur Heart J</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-9</page-range>
            <pub-id pub-id-type="pmid">11792137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-92041.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soiza</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harrild</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peden</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Hargreaves</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Risk stratification in acute coronary syndromes--does the TIMI risk score work in unselected cases?</article-title>
            <source>QJM</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-7</page-range>
            <pub-id pub-id-type="pmid">16410286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-92041.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fanaroff</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rymer</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Simel</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review.</article-title>
            <source>JAMA</source>
            <year>2015</year>
            <month>Nov</month>
            <day>10</day>
            <volume>314</volume>
            <issue>18</issue>
            <fpage>1955</fpage>
            <page-range>1955-65</page-range>
            <pub-id pub-id-type="pmid">26547467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-92041.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kao</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the TIMI, GRACE, PAMI and CADILLAC risk scores for prediction of long-term cardiovascular outcomes in Taiwanese diabetic patients with ST-segment elevation myocardial infarction: From the registry of the Taiwan Society of Cardiology.</article-title>
            <source>PLoS One</source>
            <year>2020</year>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>e0229186</fpage>
            <pub-id pub-id-type="pmid">32053694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-92041.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lev</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Kornowski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vaknin-Assa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Porter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Teplitsky</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ben-Dor</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brosh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Battler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Assali</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the predictive value of four different risk scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.</article-title>
            <source>Am J Cardiol</source>
            <year>2008</year>
            <month>Jul</month>
            <day>01</day>
            <volume>102</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-11</page-range>
            <pub-id pub-id-type="pmid">18572028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-92041.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mega</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>XQ</given-names>
              </name>
              <name>
                <surname>Snapinn</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>DiBattiste</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Th&#x000e9;roux</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.</article-title>
            <source>Am Heart J</source>
            <year>2005</year>
            <month>May</month>
            <volume>149</volume>
            <issue>5</issue>
            <fpage>846</fpage>
            <page-range>846-50</page-range>
            <pub-id pub-id-type="pmid">15894966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-92041.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Identification of patients at high risk for death and cardiac ischemic events after hospital discharge.</article-title>
            <source>Am Heart J</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>143</volume>
            <issue>6</issue>
            <fpage>966</fpage>
            <page-range>966-70</page-range>
            <pub-id pub-id-type="pmid">12075250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-92041.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction.</article-title>
            <source>Am Heart J</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>151</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-31</page-range>
            <pub-id pub-id-type="pmid">16368287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-92041.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Demopoulos</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Vicari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lakkis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>DeLucca</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>DiBattiste</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <collab>TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis in Myocardial Infarction 18 Investigators</collab>
            </person-group>
            <article-title>Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Jun</month>
            <day>21</day>
            <volume>344</volume>
            <issue>25</issue>
            <fpage>1879</fpage>
            <page-range>1879-87</page-range>
            <pub-id pub-id-type="pmid">11419424</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
